

Abstract

p53, also known as the “The guardian of the genome”, was first described in 1979 as the first identified tumor suppressor gene. It is a crucial protein in cells, where regulates the cell cycle and it is important because of its role in conserving stability by preventing genome mutation.

Our cells face many dangers, including chemicals, viruses and ionizing radiation. For instance, if key regulatory elements are damaged, the normal controls on cell growth may be blocked and the cell will rapidly multiply and grow into a tumor. p53 tumor suppressor is one of our defenses against this type of damage.

It is normally found at low levels, but when DNA damage is sensed, its levels rise and it adopts its active tetramer conformation, and initiates protective measures acting as an “emergency brake”. p53 binds to many regulatory sites in the genome, acting as a transcription factor, and begins production of proteins that halt cell division until the damage is repaired. Or, if the damage is too severe, it initiates the process of apoptosis, which directs the cell to commit suicide, permanently removing the damage.

Therefore, the dissection of its apoptotic pathway it is of great importance to understand the key points of the mechanisms underlying in taking decisions and cell fate in order to design new cancer therapies.

P53 Overview

Function

Once activated, it acts as a transcriptional activator or transrepressor of genes involved in different cellular processes such as angiogenesis, growth arrest, DNA repair and apoptosis.

Choice of response

Different promotor affinities for P53

- **Growth arrest:** P21 promotor ↑ affinity, activated at low levels
- **Apoptosis:** higher levels and extensive stress


MDM2-P53 Regulation

MDM2 Inhibits p53

-Through its ubiquitin-ligase activity

-Quenching p53 transcription activity by occluding the p53 transactivation domain

P53 Shuttle from nucleus to cytoplasm for proteasome degradation




P53 Half-life: 5-20min

The apoptotic pathway

The Extrinsic pathway

Death receptors (TNF family)

- FAS
- DR5//Killer
- PERP



The Intrinsic pathway


Bcl2 Family

Bax and Bak are membrane proteins of the outer mitochondrial membrane that regulate the membrane permeabilization (MOMP). When activated, they homooligomerize and form the pore.

They can be activated by:

- **tBid and Bim**
- **Directly by p53**
- Being released from **Bcl2**, which is an anti-apoptotic protein that represses Bax and Bak. When p53 is activated, it binds to Bcl2 thereby allowing them to form the MOMP.

MOMP




MOMP formation allows the release of caspase activation molecules such as:

- Cytochrome C
- SMAC/DIABLO
- EndoG1

Apoptosome and caspases

Apoptosome = Apaf-1 + Cytochrome C + caspase 9



Activation of effector caspases

APOPTOSIS

Activation

Apoptotic-related gene induction



TARGET GENES: those with P53 responsive elements

INDUCED GENES	FUNCTION
BAX	Mitochondrial pore protein
PUMA	Pro-apoptotic BH3 protein associated with Bcl2, promote Cyt C release
PERP	Pro-apoptotic transmembrane protein
NOXA	Associated with Bcl2, promote Cyt C release
Bcl2	Anti-apoptotic BH3 protein
PIG3	Apoptosis by regulation of redox potential
P53AIP	Dissipate mitochondrial potential
NF-KB	Transcription factor, mediator of TNF receptor signaling
FAS	Death receptor, procaspase 9 activation
FAS1/APO1	Death receptor ligand
DR5/KILLER	Death receptor
IGF-BP3	IGF binding protein 3, anti-mitogenic and pro-apoptotic
PIDD	"P53-induced protein with death domain", participates in death receptor signaling
APAF1	Adaptor protein for caspase 9 activation
HTRA2	Serine protease
MDM2	P53 regulator, Ubiquitin-ligase

Role of PIGs and ROS

- ROS are downstream mediators of apoptosis
- Several P53 induced genes (PIGs) are related to oxidative stress

Polyak et al. model:

1. Transcription induction of REDOX related genes
2. Formation of ROS
3. Oxidative degradation of mitochondrial components culminating in cell death

Table 1. p53 induced genes (PIGs) (Polyak et al.)

Gene Name	Protein Name	Notes
p21	Cdk2 Inhibitor	Induces G1 arrest
p27	Cdk2 Inhibitor	Induces G1 arrest
p107	Cdk2 Inhibitor	Induces G1 arrest
p130	Cdk2 Inhibitor	Induces G1 arrest
p16	Cdk2 Inhibitor	Induces G1 arrest
p19	Cdk2 Inhibitor	Induces G1 arrest
p21	Cdk2 Inhibitor	Induces G1 arrest
p27	Cdk2 Inhibitor	Induces G1 arrest
p107	Cdk2 Inhibitor	Induces G1 arrest
p130	Cdk2 Inhibitor	Induces G1 arrest
p16	Cdk2 Inhibitor	Induces G1 arrest
p19	Cdk2 Inhibitor	Induces G1 arrest

PIG3 → bioactivation of quinones → ROS production → apoptosis

Convenient apoptosis

- ✓ **Plant meristems:** **TED2** → high homology with PIG3 : ↑ ROS
- ✓ **Cancer therapy** → control of P53, induce apoptosis in target cells
- ✓ **Nutlin:** small molecule that lead to P53-MDM2 disruption

Conclusion

- P53 follows a complex regulation mechanism which enables the cell to respond accordingly with the extent of stress or damage.
- MDM2, post translational modifications and its different structural domains, is what provides P53 with its accurate sensitivity.
- The mitochondrial pore (MOMP) is under the regulation of a complex network of membrane proteins that are also transcriptionally regulated by P53.
- PIG3 and ROS are important for the apoptosis followed by oxidative stress in response to P53.
- P53 is a good candidate for cancer therapy. If we are able to control the induction of apoptosis, we could target and induce the apoptosis in cancer cells.

“Further understanding of the apoptotic pathway is without doubt a crucial step towards the development of new cancer therapies”

References

- B. Vogelstein, D. Lane, and J. Levine, “Surfing the p53 network,” *Nature*, vol. 408, no. 6810, pp. 307–31, Nov. 2000.
- D. P. Lane, “Cancer: p53, guardian of the genome,” *Nature*, vol. 358, no. 6381, pp. 15–6, Jul. 1992.
- F. Toledo and G. M. Wahl, “Regulating the p53 pathway in vitro hypotheses, in vivo veritas,” *Nature reviews. Cancer*, vol. 6, no. 12, pp. 909–23, Dec. 2006.
- J. S. Fridman and S. W. Lowe, “Control of apoptosis by p53,” *Oncogene*, vol. 22, no. 56, pp. 9030–40, Dec. 2003.
- K. Polyak, Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein, “A model for p53-induced apoptosis,” *Nature*, vol. 389, no. 6648, pp. 300–5, Sep. 1997.
- L. T. Vassilev, “MDM2 inhibitors for cancer therapy,” *Trends in molecular medicine*, vol. 13, no. 1, pp. 23–31, Jan. 2007.
- M. Mihara, S. Erster, A. Zaika, O. Petrenko, T. Chittenden, P. Pancoska, and U. M. Moll, “P53 Has a Direct Apoptogenic Role At the Mitochondria,” *Molecular cell*, vol. 11, no. 3, pp. 577–90, Mar. 2003.
- S. Cory and J. M. Adams, “The Bcl2 family: regulators of the cellular life-or-death switch,” *Nature reviews. Cancer*, vol. 2, no. 9, pp. 647–56, Sep. 2002.
- S. Haupt, M. Berger, Z. Goldberg, and V. Haefliger, “Apoptosis – the p53 network,” *Journal of cell science*, vol. 116, no. Pt 20, pp. 4077–85, Oct. 2003.
- T. Soussi, E. Hickman, “The role of p53 and p68 in apoptosis and cancer,” *Current Opinion in Genetics & Development*, vol. 12, no. 1, pp. 60–66, Feb. 2002.
- Websites: Protein data bank, p53.free.fr